Details for Patent: 9,981,015
✉ Email this page to a colleague
Title: | Treatment of short bowel syndrome patients with colon-in-continuity |
Abstract: | Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. |
Inventor(s): | Sanguinetti; Elizabeth L. (Salt Lake City, UT), Marriott; Thomas B. (Sandy, UT), Lopansri; Jennifer (Park City, UT), Blosch; Consuelo M. (Seattle, WA) |
Assignee: | Shire-NPS Pharmaceuticals, Inc. (Lexington, MA) |
Filing Date: | Oct 05, 2016 |
Application Number: | 15/286,171 |
Claims: | 1. A method of reducing rapid gastric emptying in an adult human patient having short bowel syndrome and rapid gastric emptying, who receives parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce the speed of gastric emptying. 2. The method of claim 1, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 .mu.g/kg. 3. The method of claim 2, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 .mu.g/kg. 4. The method of claim 1, wherein the [Gly2]hGLP-2 is administered by subcutaneous injection. 5. The method of claim 4, wherein the subcutaneous injection is into the abdomen, thigh, or arm. 6. The method of claim 1, wherein said regimen comprises administration of the [Gly2]hGLP-2 over a period of at least 21 days. 7. The method of claim 1, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 .mu.g/kg by subcutaneous injection. |